Product/Composition:- | Denosumab |
---|---|
Strength:- | 60 mg/mL, 120 mg/1.7 mL |
Form:- | Injection |
Reference Brands:- | Prolia, Xgeva |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Denosumab is available as 60 mg (Prolia) and 120 mg (Xgeva) prefilled syringes for osteoporosis and cancer-related bone conditions. Ideal for global pharma B2B sourcing.
Denosumab is a leading RANKL-inhibiting monoclonal antibody used in the treatment of osteoporosis, cancer-related bone loss, and bone metastases. Available as a 60 mg/mL prefilled syringe (Prolia®) for biannual dosing and 120 mg/1.7 mL (Xgeva®) for monthly administration, Denosumab offers effective and long-acting bone protection. Trusted globally under Amgen's Prolia and Xgeva brands, it is approved across the US and EU. Denosumab is manufactured in GMP-certified facilities and is available for B2B pharmaceutical distribution, including hospitals and oncology clinics. Contact us for bulk export, COAs, and regulatory documentation.